Therefore, targeting CARM1 enzymatic activity or peptide mimics interfering CARM1-mediated GATAD2A/2B methylation will provide a new therapeutic avenue for treating breast cancer as well as other CARM1-dependent cancers. This evidence concerns the gene CARM1 and breast carcinoma.